Related Experiment Video
Updated: Jun 23, 2026

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
Activation of AMPK inhibits inflammation in MRL/lpr mouse mesangial cells
Abstract:
Recent reports show that 5-amino-4-imidazole carboxamide riboside (AICAR), a pharmacological activator of AMP-activated protein kinase (AMPK), inhibits the lipopolysaccharide (LPS)-induced production of proinflammatory cytokines. MRL/MPJ-Fas(lpr) (MRL/lpr) mice show an intrinsic decreased threshold for the production of inflammatory mediators when stimulated. In our current studies, we sought to determine if AMPK activation would inhibit inflammatory mediator production in stimulated kidney mesangial cells. Cultured mesangial cells from MRL/lpr mice were treated with AICAR and stimulated with LPS/interferon (IFN)-gamma. AICAR decreased dose-dependently inducible nitric oxide synthase (iNOS), cyclooxygenase-2 and interleukin-6 production in LPS/IFN-gamma-stimulated mesangial cells. Mechanistically, AICAR inhibited the LPS/IFN-gamma-stimulated PI3K/Akt signalling inflammatory cascade but did not affect LPS/IFN-gamma-mediated inhibitory kappa B phosphorylation or nuclear factor (NF)-kappaB (p65) nuclear translocation. Treatment with the adenosine kinase inhibitor 5'-iodotubercidin blocked the ability of AICAR to activate AMPK and prevented AICAR from inhibiting the LPS/IFN-gamma-stimulated PI3K/Akt pathway and attenuating iNOS expression. Taken together, these observations suggest that AICAR inhibits LPS/IFN-gamma-induced Akt phosphorylation through AMPK activation and may serve as a potential therapeutic target in inflammatory diseases.
Insights
AMP-activated protein kinase (AMPK) activation by AICAR inhibits inflammatory mediator production in kidney cells. This suggests AICAR may be a therapeutic target for inflammatory diseases.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- Lipopolysaccharide (LPS) and interferon-gamma (IFN-gamma) stimulate inflammatory mediator production.
- MRL/lpr mice exhibit a heightened inflammatory response.
- AMP-activated protein kinase (AMPK) activation by 5-amino-4-imidazole carboxamide riboside (AICAR) is known to inhibit certain inflammatory pathways.
Purpose of the Study:
- To investigate the effect of AMPK activation on inflammatory mediator production in stimulated kidney mesangial cells from MRL/lpr mice.
- To elucidate the signaling pathways involved in AICAR's anti-inflammatory effects in these cells.
Main Methods:
- Primary kidney mesangial cells from MRL/lpr mice were cultured.
- Cells were treated with AICAR and stimulated with LPS/IFN-gamma.
- Levels of inducible nitric oxide synthase (iNOS), cyclooxygenase-2, and interleukin-6 were measured.
- Signaling pathways including PI3K/Akt and NF-kappaB were analyzed.
- The role of adenosine kinase was assessed using 5'-iodotubercidin.
Main Results:
- AICAR dose-dependently decreased iNOS, cyclooxygenase-2, and interleukin-6 production.
- AICAR inhibited the LPS/IFN-gamma-stimulated PI3K/Akt signaling pathway.
- AICAR did not affect LPS/IFN-gamma-mediated NF-kappaB phosphorylation or nuclear translocation.
- Inhibition of adenosine kinase blocked AICAR's AMPK activation and anti-inflammatory effects.
Conclusions:
- AMPK activation by AICAR inhibits inflammatory mediator production in kidney mesangial cells.
- The mechanism involves the inhibition of the PI3K/Akt pathway via AMPK activation.
- AICAR demonstrates potential as a therapeutic agent for inflammatory diseases.
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
cAMP-dependent Protein Kinase Pathways
MAPK Signaling Cascades
The JAK-STAT Signaling Pathway